Whole Blood Microfluidic Chip for Multiplex Allergy Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for antibiotic and food allergies are limited by their lack of sensitivity, specificity, and require invasive procedures that can cause adverse reactions, and there is a need for a reliable and timely diagnostic tool for accurate allergy detection.
Innovation Solution
A microfluidic chip and cellular-based immunological algorithm that detects immunological responses to foods, antibiotics, and drugs via biomarkers in a single analysis step, using whole blood samples, without requiring oral or dermal allergen administration, and includes a weighted mathematical algorithm and deep learning for accurate readouts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If in vivo testing methods (scratch, puncture, prick tests) are used to diagnose allergies, then diagnostic capability is provided, but patient safety deteriorates due to potential anaphylaxis and morbidity
Solution Approach 1:
The patent introduces an in vitro intermediary testing system that mediates between the need for diagnostic capability and the harm of direct allergen exposure. Whole blood samples are tested in a controlled laboratory environment using microfluidic devices, allowing allergen-antibody interactions to be observed without direct patient exposure to high doses of allergens that cause anaphylaxis
Solution Approach 2:
The patent replaces the mechanical/physical in vivo testing system (skin punctures, intradermal injections) with an in vitro biochemical system. The mechanical act of injecting allergens into patient tissue is substituted with biochemical assays in controlled in vitro environments, eliminating the harmful mechanical trauma and allergic reaction risks
2Reliability
If PRE-PEN skin testing is used for penicillin allergy diagnosis, then IgE-mediated reactions are detected, but sensitivity deteriorates by missing 10% of cases caused by minor determinants
Solution Approach 1:
The patent segments the allergy testing process into multiple parallel assays, each targeting different allergen determinants. Instead of relying on a single PRE-PEN test for penicillin, the system performs simultaneous testing against multiple allergens including major and minor penicillin determinants, allowing comprehensive detection of IgE-mediated reactions across different allergen classes
Solution Approach 2:
The patent creates a universal testing platform that can detect multiple types of allergic reactions simultaneously. The microfluidic device and automated system are designed to handle diverse allergen types (foods, drugs, antibiotics) and multiple reaction mechanisms (IgE-mediated, non-IgE-mediated), providing a multi-functional diagnostic tool that surpasses the single-function PRE-PEN test
3Measurement precision
If multiple separate allergy tests are performed for different allergens, then comprehensive allergy profiling is achieved, but testing time and complexity increase
Solution Approach 1:
The patent merges multiple separate allergy tests into a single integrated microfluidic device. The system combines multiple allergen exposures, incubation chambers, and detection assays into one unified platform that processes all tests simultaneously using a single blood sample, eliminating the need for sequential testing and reducing total testing time
Solution Approach 2:
The patent performs preliminary preparation of the microfluidic device with multiple allergens pre-loaded into separate chambers before patient sampling. This preliminary action allows the system to immediately begin simultaneous testing across multiple allergens once the blood sample is introduced, eliminating setup time between tests and enabling comprehensive profiling in a single workflow
4Measurement precision
If manual interpretation of allergy test results is performed by trained physicians, then diagnostic accuracy is improved, but operational complexity and cost increase
Solution Approach 1:
The patent implements a self-service automated interpretation system where the microfluidic device and associated software automatically analyze test results without requiring trained physicians or immunologists. The system uses pre-programmed algorithms to interpret reaction patterns, calculate risk scores, and generate diagnostic reports, making the interpretation process self-service and eliminating the need for specialized human expertise
Solution Approach 2:
The patent replaces the human cognitive system (physician interpretation) with an automated computational system. The complex mental processes of pattern recognition, differential diagnosis, and risk assessment performed by trained physicians are substituted with algorithmic analysis, image processing, and automated scoring systems that provide consistent, objective interpretation without human variability or subjectivity
Data Source
AI summary
The present invention describes a whole blood assay chip that enables separation of the cellular compartment from surrounding plasma, facilitating multiplexed measurement of otherwise difficult to detect soluble factors produced upon cellular stimulation. The invention is a microfluidic chip with an incubation chamber comprising an inlet, an outlet, and a fluidic barrier. Using this platform, the cellular compartment can be stimulated with various substances and levels of immunologic biomarkers could be measured. Through a proprietary immunologic algorithm described herein, this would allow for the diagnosis of an allergic response to foods, antibiotics, and/or other drugs. Additional applications of the invention besides allergy testing could include pregnancy testing, blood type, and medical applications requiring whole blood cellular stimulation readouts.